|
- Nipocalimab - Wikipedia
Nipocalimab, sold under the brand name Imaavy, is a monoclonal antibody used for the treatment of generalized myasthenia gravis [1] It is a neonatal Fc receptor blocker [1]
- Nipocalimab Uses, Side Effects Warnings - Drugs. com
Nipocalimab is used to treat myasthenia gravis in adults and children at least 12 years old Your doctor will make sure you have the correct antibody type to be treated with nipocalimab
- Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has . . .
Nipocalimab is a human immunoglobulin G (IgG)1 monoclonal antibody that binds to the neonatal Fc receptor (FcRn) with high specificity and high affinity at both neutral (extracellular) and acidic (intracellular) pH, resulting in the reduction of circulating IgG levels, including those of pathogenic IgG antibodies
- IMAAVYTM (nipocalimab-aahu) showed greater sustained disease control . . .
IMAAVY TM (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
- Nipocalimab by Janssen: An FcRn Blocker Explained
An overview of nipocalimab, an investigational FcRn blocker designed to treat autoimmune diseases by accelerating the removal of pathogenic IgG antibodies
- Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and . . .
Nipocalimab, a neonatal Fc receptor (FcRn) blocker, is under development for the treatment of multiple IgG autoantibody- or alloantibody-driven diseases
- Nipocalimab showed greater sustained disease control versus approved . . .
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG IMAAVY (nipocalimab), an FcRn blocker, received U S FDA approval earlier this year for the broad population of individuals living with gMG, including anti-AChR and
- IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control . . .
Nipocalimab is continuing to be investigated across three key segments in the autoantibody space including Rare Autoantibody diseases, Maternal Fetal diseases mediated by maternal alloantibodies
|
|
|